Comparative Immunogenicity of Respiratory Virus Vaccines (CIRV2) Study — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Comparative Immunogenicity of Respiratory Virus Vaccines (CIRV2) Study — Stella

Recruiting

Back to COVID -19 trials

Phase 4 — Post-approval study. The treatment has been approved, but researchers continue monitoring it in a large population over time.

Trial locations(1 site)

United States

Walter Reed National Military Medical Center, Bethesda, Maryland

Key details

Phase

Post-approval study

Sponsor

Henry M. Jackson Foundation for the Advancement of Military Medicine

Collaborators

Centers for Disease Control and Prevention, U.S. Food and Drug Administration (FDA)

Enrollment target

~54 participants

Started

November 2025

Primary completion

September 2027

Age range

18 Years – 79 Years

Last updated December 2025

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.

View full record on ClinicalTrials.gov